Financial News

Financial Report: Biogen

Growth in the quarter driven by TECFIDERA, ELOCTATE and ALPROLIX

Biogen

2Q Revenues: $2.9 billion (+12%)

2Q Earnings: $1.1 billion (+13%)

Comments: Growth in the quarter was driven by the multiple sclerosis and hemophilia businesses. TECFIDERA sales were up 12% to $987 million. AVONEX sales were down 2% to $606 million, while PLEGRIDY sales were up 65% to $123 million. TYSABRI sales were $497 million, up 7%. ELOCTATE and ALPROLIX sales were $125 million, up 68%, and $80 million, up 48%, respectively.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters